Humana Inc. Stock
Humana Inc. Stock
Humana Inc. (Symbol: HUM) is a leading healthcare and wellness company headquartered in Louisville, Kentucky, specializing in offering a diversified range of health insurance, wellness programs, and managed care plans to individual, group, government, and military customers. With a strong commitment to providing personalized, affordable, and high-quality healthcare solutions, Humana emphasizes on simplifying access and meeting the evolving needs of its vast clientele through leveraging data analytics, technology, and innovation. As a publicly traded entity, Humana’s stock is listed on the New York Stock Exchange, and it forms part of the esteemed S&P 500 index, reflecting its significant impact and presence within the highly competitive healthcare sector.
Pros and Cons of Humana Inc. in the next few years
Pros
Cons
Performance of Humana Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Humana Inc. | -2.380% | -4.000% | -0.592% | 65.762% | 53.005% | -18.288% | -15.044% |
| Cigna Corp. | 3.870% | 2.894% | 3.226% | 1.406% | 9.168% | -4.156% | 32.197% |
| Centene Corp. | -2.700% | -2.323% | -2.391% | 133.002% | 62.950% | -11.762% | -6.100% |
| UnitedHealth Group Inc. | 2.990% | -0.595% | -2.131% | 53.499% | 31.121% | -20.304% | 4.643% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Humana Inc. (HUM.US) - FY2025 Annual Report
Humana's financial position appears to be under considerable strain. While total revenue reached a record $129.7 billion, reflecting consistent top-line expansion, profitability has deteriorated sharply. Net income for FY2025 came in at approximately $1.19 billion, which is less than half of what the company earned just two years earlier and represents a negative compound annual growth rate of around 20% over the past four years. The stock price, at $257.84, sits near a five-year low, which could suggest the market has been pricing in these headwinds.
The most striking feature is the persistent compression of profitability despite growing revenues. The operating margin, which stood above 4% in FY2022, has been halved to just over 2%. Similarly, the net margin has dwindled to under 1%. This divergence between revenue growth of about 10% year-over-year and a slight decline in net income could indicate significant pressure on the company's medical cost ratios. The benefits expense line, which represents the core cost of providing care, appears to be the primary driver, having grown to over $110 billion and outpacing premium revenue growth in a way that has squeezed the spread.
Comments
News
SS&C Technologies Q2 Earnings Call Highlights
Key Points
- Interested in SS&C Technologies Holdings, Inc.? Here are five stocks we like better.
- SS&C Technologies posted record second-quarter 2026 results, with adjusted revenue up 10.3% to
Community Health Systems Q2 Earnings Call Highlights
Key Points
- Interested in Community Health Systems, Inc.? Here are five stocks we like better.
- Community Health Systems cut its full-year 2026 outlook after second-quarter results came in below
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound
Key Points
- Interested in Eli Lilly and Company? Here are five stocks we like better.
- Eli Lilly, Humana, and DexCom have driven a broad healthcare sector recovery, with the sector gaining 5.4%